| ○ |
|
菱田明 |
焼津市立総合病院 名誉院長 |
| 腎臓内科学 |
（業績・実績その１）
Analysis of 2897 hospitalization events for patients with chronic kidney disease: results from CKD-JAC study. Iimuro S, Kaneko T, Ohashi Y, Watanabe T, Nitta K, Akizawa T, Matsuo S, Imai E, Makino H, Hishida A; CKD-JAC Investigators. Clin Exp Nephrol. 23(7):956-968. 2019
|
（業績・実績その２）
Cardiovascular events and death in Japanese patients with chronic kidney disease. Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, Matsuo S, Imai E, Makino H, Hishida A; CKD-JAC Investigators. Kidney Int. 91(1):227-234. 2017
|
（業績・実績その３）
Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate. Matsushita K, Chen J, Sang Y, Ballew SH, Shimazaki R, Fukagawa M, Imai E, Coresh J, Hishida A. Kidney Int. 90(5):1109-1114. 2016
|
|
| |
|
佐々木 成 |
特定医療法人社団清湘会・理事長
東京医科歯科大学・名誉教授
|
| 腎臓内科学 |
| Alkali treatment stabilizes fluctuations of urine AQP2 values measured by ELISA. Sasaki S, Saijo Y, Ohmoto Y, et al. Clin Exp Nephrol 20: 450-455, 2016
|
| Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study. Iimori S, Naito S, Noda Y, Sasaki S et al. Nephrology 20: 601-608, 2015
|
| Hereditary nephrogenic diabetes insipidus in Japanese patients: analysis of 78 families and report of 22 new mutations in AVPR2 and AQP2. Sasaki S, Chiga M, Kikuchi E, et al. Clin Exp Nephrol. 17:338-344, 2013
|
|
| |
|
富野 康日己 |
医療法人社団松和会 理事長 |
| 腎臓内科学 |
| “How to treat patients with chronic kidney disease: With special focus on IgA nephropathy” Yasuhiko Tomino. Nephrology. 2018 Oct. 23; Vol.23 Suppl. 4 :76-79
|
| “Rac1 in podocytes promotes glomerular repair and limits the formation of sclerosis” Rin Asao, Takuto Seki, Miyuki Takagi, Hiroyuki Yamada, Fumiko Kodama, Yoshiko Hosoe-Nagai, Eriko Tanaka, Juan Alejandro Oliva Trejo, Kanae Yamamoto-Nonaka, Yu Sasaki, Teruo Hidaka, Takashi Ueno, Motoko Yanagita, Yusuke Suzuki, Yasuhiko Tomino, Katsuhiko Asanuma. Sci Rep. 2018 Mar 22; 8(1):5061.
|
| “Far-infrared therapy for secondary vascular access patency of hemodialysis patients” Hiroaki Io, Junichiro Nakata, Rumi Aoyama, Hiroyuki Inoshita, Takanori Nakano, Masanori Ishizaka, Mitsumine Fukui, Yasuhiko Tomino and Yusuke Suzuki. Renal Replacement Therapy (2019)5:31
DOI: 10/1186/s41100-019-0224-9
|
|
| |
|
東原 英二 |
杏林大学医学部 遺伝性腎疾患研究講座
|
| 多発性嚢胞腎、泌尿器 |
| Eiji Higashihara, Shigeo Horie, Satoru Muto, Haruna Kawano, Mitsuhiro Tanbo, Tsuyoshi Yamaguchi, Satoru Taguchi, Shinya Kaname, Kenichi Tokoyama, Tatsuya Yoshioka, Toshihito Furukawa, Hiroshi Fukuhara. Imaging Identification of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease: Simple Eligibility Criterion for Tolvaptan. Am J Nephrol. DOI: 10.1159/000511797. 2020.
|
| Eiji Higashihara, Hiroshi Fukuhara, John Ouyang, Jennifer Lee, Kikuo Nutahara, Mitsuhiro Tanbo, Tsuyoshi Yamaguchi, Satoru Taguchi, Satoshi Muto, Shinya Kaname, Isao Miyazaki, Shigeo Horie. Estimation of changes in kidney volume growth rate in autosomal dominant polycystic kidney disease. Kidney Int Reports. 5: 1459-1471. 2020.
|
| Eiji Higashihara, Kouji Yamamoto, Shinya Kaname, Takatsugu Okegawa, Mitsuhiro Tanbo, Tsuyoshi Yamaguchi, Kaori Shigemori, Isao Miyazaki, Kenichi Yokoyama, Kikuo Nutahara. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 23: 100-111. 2019.
|
|
